CSPHF News and Press, CStone Pharmaceuticals - Ordinary Shares

2024-06-02 03:00:00 ET Summary Suzhou MediLink partners with BioNTech to use its antibody-drug conjugate platform, receiving an upfront payment of $25 million and up to $1.8 billion in milestones. Asahi Kasei offers $1.1 billion to acquire Calliditas Therapeutics, aiming to expand...

2024-05-26 02:45:00 ET Summary Jiangsu Hengrui Medicine out-licenses global rights for its GLP-1 candidates to US startup Hercules in a deal worth up to $6 billion. Shanghai Degron Therapeutics partners with Takeda to identify multiple targets in oncology, neuroscience, and inflam...

2024-03-14 05:50:00 ET Summary CEO Jason Yang has increased his CStone stake multiple times over the past 18 months to 4.79% of outstanding shares, signaling confidence in the company. The drug developer slimmed down its operations last year and licensed out several products, swit...

2023-12-24 13:30:00 ET Summary GSK acquired ex-Greater China rights to a second ADC from Jiangsu’s Hansoh Pharma in a $1.7 billion agreement. Boston’s Nona Biosciences out-licensed global rights for its MSLN-targeted ADC to Pfizer for $53 million in upfront and near-...

2023-12-17 02:00:00 ET Summary SystImmune out-licenses global rights for a bispecific ADC to Bristol Myers Squibb in an $8.4 billion agreement. Evive Biotech forms an antibody discovery collaboration with Nona Biosciences to accelerate the process of antibody discovery and drug de...

2023-11-05 02:15:00 ET Summary Jiangsu Hengrui Pharma out-licensed global rights (ex-China) for its next-gen PARP1 inhibitor to Germany’s Merck KGaA. BioLineRx, an Israeli biotech, out-licensed China rights to a stem cell mobilizer for multiple myeloma and stem cell disease...

2023-06-29 13:31:15 ET Summary Shares of antibody discovery platform concern OmniAb have recovered marginally from their SPAC-birthed debut, when they were down 61% in their first day of regular-way trading. With three approved antibody therapies and 24 in the clinic, the company&...

2023-05-19 05:00:00 ET Summary The companies parted ways after tighter approval rules made it harder to market their new drugs in the U.S. CStone partner EQRx has launched a restructuring drive and layoffs to tackle its financial woes, keeping only one drug pipeline running. A...

2023-05-14 14:20:00 ET Summary Bliss Biopharma (Hangzhou) announced it may out-license global rights (ex-China) for its HER2 ADC to Japan’s Eisai Pharma in a deal with a potential value of $2 billion. Shanghai Junshi Bio out-licensed regional rights for its anti-PD-1 mAb to...

Qiming Venture Partners closed two new China healthcare and technology funds with $3.2 billion in fresh capital, both of them at their hard cap limits. Suzhou CStone Pharma announced that Gavreto® (pralsetinib) was approved in Hong Kong to treat adult patients with RET fusion-pos...